FBT is an exchange-traded fund — it holds a basket of underlying assets rather than being a single operating company.
Company fundamentals like P/E, revenue, EPS and profit margins don't apply to a fund — its value comes from the assets it holds, not its own earnings. Use the price chart, options and model forecast below for fund-level analysis.
An institutional-grade, numbers-driven thesis on FBT — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 18, 2026, TradersQuant's model rates First Trust NYSE Arca Biotechnology Index Fund (FBT) 56/100 with a 12-month base-case forecast of $319.72 — +22.2% versus the current price of $261.68. First Trust NYSE Arca Biotechnology Index Fund trades at $261.68 in the Financial Services sector, with a market capitalisation of $1.63B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for FBT is $319.72, implying +22.2% versus the current price. The model's 12-month scenario range runs from $292.20 (bear) to $363.35 (bull), with a base case of $319.72.
FBT currently carries a TradersQuant composite score of 56/100, which we read as a neutral-to-watch signal. Our 12-month price target of $319.72 implies +22.2% from $261.68. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for FBT is $319.72, about +22.2% versus the latest price of $261.68.
TradersQuant's 12-month model forecast for FBT is a base case of $319.72, ranging from $292.20 (bear) to $363.35 (bull), an expected return of +22.2%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for FBT over the next 12 months is $319.72 in the base case (bear $292.20, bull $363.35), versus today's price of $261.68. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for FBT — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates FBT's fair value at $334.82, implying +28.0% of expected upside versus the current price.
First Trust NYSE Arca Biotechnology Index Fund does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
